Stand Up To Cancer Awards $73.6 Million
Stand Up To Cancer (SU2C) has awarded the first round of three-year grants, totaling $73.6 million, to five multi-disciplinary, multi-institutional research Dream Teams. SU2C is the Entertainment Industry Foundation’s charitable initiative supporting groundbreaking research aimed at getting new cancer treatments to patients in an accelerated timeframe. In the U.S. alone, one out of three women and one out of two men will be diagnosed with cancer in their lifetimes. Up to 562,340 people are expected to die of cancer in the United States this year. SU2C hopes to change this.
The five Dream Teams are made of 7 leaders, 4 co-leaders and 27 principal researchers. They come from over 20 leading institutions, with more than 300 individuals participating in total. Each team also has at least two members from patient advocacy groups to ensure that the perspective of the patients and survivors they represent will be integrated into the research on an ongoing basis.
The teams are listed below in alphabetical order according to the name of the leaders:
• “Bringing Epigenetic Therapy to the Forefront of Cancer Management” / Leader: Stephen B. Baylin, M.D., Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Co-Leader: Peter A. Jones, Ph.D., Distinguished Professor of Urology and Biochemistry & Molecular Biology, University of Southern California;
• “Targeting the PI3K Pathway in Women’s Cancers” / Leader: Lewis C. Cantley, Ph.D., Chief of the Division of Signal Transduction at Beth Israel Deaconess Medical Center; Co-Leaders: Charles L. Sawyers, M.D., Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, and Gordon B. Mills, M.D., Ph.D., Chair, Department of Systems Biology, University of Texas M. D. Anderson Cancer Center;
• “An Integrated Approach to Targeting Molecular Breast Cancer Molecular Subtypes and Their “Resistance” Phenotypes” / Leaders: Joe W. Gray, Ph.D., Life Sciences Division Director, Lawrence Berkeley National Laboratory, and Dennis J. Slamon, M.D., Ph.D., Director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center;
• “Bioengineering and Clinical Applications of Circulating Tumor Cells Chip” / Leader: Daniel A. Haber, M.D., Ph.D., Director of the Massachusetts General Hospital Cancer Center; Co-Leader: Mehmet Toner, Ph.D., Professor of Biomedical Engineering, Harvard Medical School; and
• “Cutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer” / Leaders: Craig B. Thompson, M.D., Director, Abramson Cancer Center at the University of Pennsylvania, and Daniel D. Von Hoff, M.D., Senior Investigator and Physician in Chief at the Translational Research Genomics Institute (TGen).
It is hoped that the research done through the Dream Team projects will impact the diagnosis and treatment of a wide range of cancers in adults and children including, but not limited to pancreatic, breast, ovarian, cervical, uterine, brain, lung, prostate, rectal and colon, which represent two thirds of all U.S. cancer deaths.
For additional information on Stand Up To Cancer, visit www.su2c.org